RayBiotech, a developer of antibody and protein array technologies, has introduced a peptoid drug candidate and diagnostic ligand discovery service program.
The new service platform, which is aimed at the identification of novel ligands for client-driven drug targets, will involve multi-stage screening of targets against a complex combinatorial peptoid library, followed by peptoid sequence refinement and optimization.
RayBiotech said to enhance the customization of services, it will also provide synthesis of novel peptoid libraries based on the drug target's characteristics, as well as secondary functional assay validation for ligand candidates.
RayBiotech president, COO and co-founder Rani Huang said the chemical diversity and proteolytic resistance exhibited by peptoids make them ideal drug candidates.
"Peptoids provide the complexity of a peptide with the stability of a small molecule, and several have already been identified as high-affinity ligands for such optimal drug targets as G protein-coupled receptors," Huang added.
"RayBiotech's peptoid discovery services will allow the efficient identification of high-value agonists and antagonists for our clients."
